Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has announced the completion of a reverse stock split at a ratio of 1-for-240, effective as of 5:00 p.m. on December 28, 2023. The reverse stock split was previously approved by stockholders on December 20, 2023, and resulted in the reduction of outstanding common stock from approximately 192.4 million shares to approximately 801,611 shares. The action was taken to meet the continued listing criteria for the Nasdaq Capital Market. The company's common stock began trading on a split-adjusted basis on December 29, 2023, under the existing trading symbol 'AVTX'. Stockholders who would have received fractional shares as a result of the reverse stock split were instead given one whole share of common stock. The reverse stock split did not change the number of...Show More
Avalo Therapeutics, Inc. has announced the completion of a reverse stock split at a ratio of 1-for-240, effective as of 5:00 p.m. on December 28, 2023. The reverse stock split was previously approved by stockholders on December 20, 2023, and resulted in the reduction of outstanding common stock from approximately 192.4 million shares to approximately 801,611 shares. The action was taken to meet the continued listing criteria for the Nasdaq Capital Market. The company's common stock began trading on a split-adjusted basis on December 29, 2023, under the existing trading symbol 'AVTX'. Stockholders who would have received fractional shares as a result of the reverse stock split were instead given one whole share of common stock. The reverse stock split did not change the number of authorized shares or the par value per share. Adjustments will be made to the per share exercise price and number of shares issuable under all of the company's outstanding options and warrants, as well as the number of shares authorized and reserved for issuance under the company's equity incentive plan. Equiniti Trust Company, LLC is acting as the exchange agent for the reverse stock split.
Avalo Therapeutics, Inc.宣布完成反向股票拆分，比例为1比240，自2023年12月28日下午5点起生效。反向股票拆分此前已于2023年12月20日获得股东的批准，导致已发行普通股从约1.924亿股减少至约801,611股。采取该行动是为了满足纳斯达克资本市场的持续上市标准。该公司的普通股于2023年12月29日开始按拆分调整后的基础上交易，现有交易代码为 “AVTX”。相反，本来会因反向股票拆分而获得零股的股东却获得了整股普通股。反向股票拆分没有改变授权股票的数量或每股的面值。将调整公司所有已发行期权和认股权证下的每股行使价和可发行的股票数量，以及根据公司股权激励计划批准和预留发行的股票数量。Equiniti Trust Company, LLC是反向股票拆分的交易所代理。
Avalo Therapeutics, Inc.宣布完成反向股票拆分，比例为1比240，自2023年12月28日下午5点起生效。反向股票拆分此前已于2023年12月20日获得股东的批准，导致已发行普通股从约1.924亿股减少至约801,611股。采取该行动是为了满足纳斯达克资本市场的持续上市标准。该公司的普通股于2023年12月29日开始按拆分调整后的基础上交易，现有交易代码为 “AVTX”。相反，本来会因反向股票拆分而获得零股的股东却获得了整股普通股。反向股票拆分没有改变授权股票的数量或每股的面值。将调整公司所有已发行期权和认股权证下的每股行使价和可发行的股票数量，以及根据公司股权激励计划批准和预留发行的股票数量。Equiniti Trust Company, LLC是反向股票拆分的交易所代理。
有用
没用